Home > Journals > Italian Journal of Dermatology and Venereology > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2019 October;154(5) > Giornale Italiano di Dermatologia e Venereologia 2019 October;154(5):567-72



Publishing options
To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Giornale Italiano di Dermatologia e Venereologia 2019 October;154(5):567-72

DOI: 10.23736/S0392-0488.18.05791-7


language: English

Acral melanoma: correlating the clinical presentation to the mutational status

Giulia M. RAVAIOLI , Emi DIKA, Martina LAMBERTINI, Marco A. CHESSA, Pier Alessandro FANTI, Annalisa PATRIZI

Section of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

Acral lentiginous melanoma (ALM) is the most common type of malignant melanoma (MM) in Asians, Afro-Americans and Middle-Easterners. It represents 1.5-10% of all MM cases, being the most common histological type of MM arising on palms, soles and nail apparatus, which is more generically defined as acral MM. To date no risk factors have been officially established, however a history of trauma may be involved in the pathogenesis of acral MM. This shows heterogeneous clinical features and frequently presents with advanced stage and aggressive behavior, often as a result of misdiagnosis or delayed identification. Dermoscopy is helpful for an early diagnosis of ALM: the most characteristic dermoscopic patterns are the parallel ridge and the irregular diffuse pigmentation. On histopathology ALM displays a lentiginous growth pattern, with melanocytes arranged as solitary units along the basilar epidermis, without notable pagetoid growth in the early stage. Not all acral MMs present a lentiginous pattern: superficial spreading melanoma and nodular melanoma patterns are also possible. Novel studies investigating the biologic characteristics of acral MM reported variable results: the overall mutational rates ranged respectively between 8.5% and 23% for KIT, between 3.6% and 33.3% for BRAF and between 3% and 47% for NRAS in ALMs. Increasing attention has been recently given to other genes, such as telomerase reverse transcriptase, platelet-derived growth factor receptor alfa and cyclin D1. Larger molecular investigations urge to describe the molecular profile of acral MM, to allow the development of specific targeted therapies.

KEY WORDS: Melanoma; Genetics; Dermoscopy

top of page